Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4.14% | 50.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.14% | 50.12% | |||
| Cost of Revenue | -19.62% | 70.22% | |||
| Gross Profit | 12.35% | 44.24% | |||
| SG&A Expenses | 9.16% | -3.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.75% | 13.35% | |||
| Operating Income | 18.49% | 3,044.52% | |||
| Income Before Tax | 22.55% | 1,305.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.46% | 1,305.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.46% | 1,305.92% | |||
| EBIT | 18.49% | 3,044.52% | |||
| EBITDA | 17.67% | 1,283.68% | |||
| EPS Basic | 15.16% | 1,302.21% | |||
| Normalized Basic EPS | 22.22% | 1,301.91% | |||
| EPS Diluted | 13.91% | 1,292.50% | |||
| Normalized Diluted EPS | 20.25% | 1,298.64% | |||
| Average Basic Shares Outstanding | 0.27% | 0.29% | |||
| Average Diluted Shares Outstanding | 1.92% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||